Based on Galderma multi-center, randomized, evaluator-blinded controlled studies (N=270):

96% Cohort Satisfaction: Subjects reported observable lip fullness and structural improvement at 8 weeks post-injection.

78% Longevity Rate: Sustained volumetric retention maintained at 12 months.

20% Volume Efficiency: Achieved equivalent aesthetic endpoints utilizing 20% less product volume compared to non-XpresHAn baseline fillers.

Utilizes a proprietary manufacturing process adjusting the degree of cross-linking. This creates a flexible HA gel profile optimized for high-mobility perioral dynamic regions. The medium calibration particle size ensures tissue integration while mitigating the Tyndall effect in superficial submucosal planes.

Must be administered exclusively by licensed medical practitioners holding formal training in facial anatomy and dermal filler injection techniques.

Absolute Contraindications:

• Documented history of severe allergic reactions (anaphylaxis).

• Known hypersensitivity to gram-positive bacterial proteins.

• Allergy to lidocaine or amide-type local anesthetics.

Documented Adverse Events (AEs):

Transient injection-site responses including erythema, edema, ecchymosis, induration, and pruritus. Mean resolution time for observed AEs is 3 to 7 days post-procedure without clinical intervention.